Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)

Next Previous
Trial Profile

A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACI 24 (Primary)
  • Indications Alzheimer's disease; Down syndrome; Mental retardation
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ABATE
  • Sponsors AC Immune

Most Recent Events

  • 25 Mar 2025 According to an AC Immune media release, data from this study will be presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2025) taking place in Vienna, Austria, on April 1-5, 2025
  • 13 Mar 2025 According to an AC Immune media release, interim results are expected in second half of 2025.
  • 10 Dec 2024 According to an AC Immune media release, trial will now start to evaluate the high dose of ACI-24.060 in additional patients with DS.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top